Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Translating the basic and clinical cognitive neuroscience of schizophreniato drug development and clinical trials of antipsychotic medications
Autore:
Green, MF; Braff, DL;
Indirizzi:
Univ Calif San Diego, Dept Psychiat 0804, La Jolla, CA 92093 USA Univ Calif San Diego La Jolla CA USA 92093 t 0804, La Jolla, CA 92093 USA Univ Calif San Diego, Dept Biobehav Sci, La Jolla, CA 92093 USA Univ CalifSan Diego La Jolla CA USA 92093 av Sci, La Jolla, CA 92093 USA Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA Univ Calif SanDiego La Jolla CA USA 92093 ychiat, La Jolla, CA 92093 USA
Titolo Testata:
BIOLOGICAL PSYCHIATRY
fascicolo: 4, volume: 49, anno: 2001,
pagine: 374 - 384
SICI:
0006-3223(20010215)49:4<374:TTBACC>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
TREATMENT-RESISTANT SCHIZOPHRENIA; INFORMATION-PROCESSING DEFICITS; PHENCYCLIDINE-INDUCED DEFICITS; CONTINUOUS PERFORMANCE TESTS; PREPULSE INHIBITION; SUSTAINED ATTENTION; NUCLEUS-ACCUMBENS; THOUGHT-DISORDER; GATING DEFICITS; STARTLE REFLEX;
Keywords:
schizophrenia; drug development; neurocognition; animal models;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
77
Recensione:
Indirizzi per estratti:
Indirizzo: Braff, DL Univ Calif San Diego, Dept Psychiat 0804, 9500 Gilman Dr, La Jolla, CA 92093 USA Univ Calif San Diego 9500 Gilman Dr La Jolla CA USA 92093 93 USA
Citazione:
M.F. Green e D.L. Braff, "Translating the basic and clinical cognitive neuroscience of schizophreniato drug development and clinical trials of antipsychotic medications", BIOL PSYCHI, 49(4), 2001, pp. 374-384

Abstract

Neurocognitive deficits have become increasingly important defining features of schizophrenia and its treatment. Multiple domains of neurocognitive functions are impaired in schizophrenia patients, and these impairments are considered to be core features of the disorder. Many recent reports supportthe importance of the relationship of these neurocognitive deficits to measure of "functional outcome" such as skills acquisition, social problem solving, and community outcome. Neurocognitive deficits appear to be improved with newer (atypical) antipsychotic medications across a broad range of domains in schizophrenia patients. Together with clinical neuroscience rangingfrom animal models of gating functions to early gene expression induced byantipsychotic medications has illuminated the specific neural base of neurocognitive deficits in schizophrenia and the neurobiology of antipsychotic actions. These translational basic and clinical studies provide powerful screening tools and strategies for drug development and the subsequent assessment of the clinical efficacy of new antipsychotic medications. These interlocking clinical and basic research findings have substantial implications for improving both drug development and improving clinical trials methodology for antipsychotic medications. Thus, ther is an informed translation andcross-fertilization between basic and clinical research focused on the development and assessment of putative new antipsychotic compounds. (C) 2001 Society of biological Psychiatry.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/20 alle ore 20:10:40